Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas

NCT02192359 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02192359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02192359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 5, 2016
Completion date
September 25, 2026
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent anaplastic astrocytoma, recurrent anaplastic oligoastrocytoma, recurrent anaplastic oligodendroglioma, recurrent glioblastoma, recurrent gliosarcoma, recurrent malignant glioma, recurrent who grade iii glioma